PMA device
Supartz Fx
Seikagaku Corp. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Jan 24, 2001, newest Jan 27, 2016Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "Supartz Fx"
MAUDE reports
0
Brand "Supartz Fx", since 2015
PubMed studies
4
Mentioning "Supartz Fx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Supartz Fx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 3 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Supartz Fx", any status and sponsor, newest update first.
No registered device study names "Supartz Fx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Supartz Fx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MOZ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Supartz Fx"[tiab]. The summary above synthesizes these.
- A method for establishing class III medical device equivalence: sodium hyaluronate (GenVisc 850) for the treatment of knee osteoarthritis.
Doros G, Lavin PT, Daley M, et al. · Med Devices (Auckl) · 2016Review
- Biocompatibility study of different hyaluronan products for intra-articular treatment of knee osteoarthritis.
Yoshioka K, Katayama M, Nishiyama T, et al. · BMC Musculoskelet Disord · 2019
- Review of the Mechanism of Action for Supartz FX in Knee Osteoarthritis.
Altman RD, Dasa V, Takeuchi J · Cartilage · 2018Review
- Patient-reported Outcomes of Short-term Intra-articular Hyaluronic Acid for Osteoarthritis of the Knee: A Consecutive Case Series.
Gusho CA, Jenson M · Cureus · 2019
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
- Orthovisc Sodium HyaluronateAnika Therapeutics, Inc. · PMA 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.